Blockade of costimulatory pathways of T-cell activation: The solution to acute and chronic rejection?

Current Opinion in Nephrology and Hypertension

Volumn 8, Issue 6, 1999, Pages 675-680

  Van Kooten, Cees ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN GP 39;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; GRAFT REJECTION; HUMAN; LIGAND BINDING; MOLECULAR INTERACTION; PRIORITY JOURNAL; RECEPTOR BINDING; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; ANTIGENS, CD27; ANTIGENS, CD28; ANTIGENS, CD40; CHRONIC DISEASE; GRAFT REJECTION; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 0033375587     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199911000-00004     Document Type: Article

References (56)

1. 1 Gould DS, Auchincloss H Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 1999; 20:77-82.
2. 2 Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14:233-258.
3. 3 Freeman GJ, Cardoso AA, Boussiotis VA, Anumanthan A, Groves RW, Kupper TS, et al. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor. J Immunol 1998; 161:2708-2715.
4. 4 Oosterwegel MA, Greenwald RJ, Mandelbrot DA, Lorsbach RB, Sharpe AH. CTLA-4 and T cell activation. Curr Opin Immunol 1999; 11:294-300.
5. 5 Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541-547.
6. 6 Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. Molecular basis of T cell inactivation by CTLA-4. Science 1998; 282:2263-2266. This study shows that CTLA-4 signalling directly interferes with the activation via the TCR by preventing phosphorylation of the ζ chain.
7. 7 Lin H, Rathmell JC, Gray GS, Thompson CB, Leiden JM, Alegre ML. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J Exp Med 1998; 188:199-204.
8. 8 Pearson TC, Alexander DZ, Corbascio M, Hendrix R, Ritchie SC, Linsley PS, et al. Analysis of the B7 costimulatory pathway in allograft rejection. Transplantation 1997; 63:1463-1469.
9. 9 Walunas TL, Bluestone JA. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol 1998; 160:3855-3860.
10. 10 Johnson-Leger C, Christensen J, Klaus GG. CD28 co-stimulation stabilizes the expression of the CD40 ligand on T cells. Int Immunol 1998; 10:1083-1091.
11. 11 Ford GS, Barnhart B, Shone S, Covey LR. Regulation of CD154 (CD40 ligand) mRNA stability during T cell activation. J Immunol 1999; 162:4037-4044.
12. 12 Watts TH, DeBenedette MA. T cell co-stimulatory molecules other than CD28. Curr Opin Immunol 1999; 11:286-293.
13. 13 Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397:263-266.
14. 14 Lens SM, Tesselaar K, van Oers MH, van Lier RA. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 1998; 10:491-499.
15. 15 Saoulli K, Lee SY, Cannons JL, Yeh WC, Santana A, Goldstein MD, et al. CD28-independent, TRAF2-dependent stimulation of resting T cells by 4-1BB ligand. J Exp Med 1998; 187:1849-1862.
16. 16 Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998; 161:6510-6517.
17. 17 Utku N, Heinemann T, Tullius SG, Bulwin GC, Beinke S, Blumberg RS, et al. Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Immunity 1998; 9:509-518.
18. 18 Lakkis FG. Role of cytokines in transplantation tolerance: lessons learned from gene-knockout mice. J Am Soc Nephrol 1998; 9:2361-2367.
19. 19 Wulfing C, Davis MM. A receptor/cytoskeletal movement triggered by costimulation during T cell activation. Science 1998; 282:2266-2269. This paper, together with [20•], shows that intracellular movement and reorganization of receptors have an important impact on T cell signal transduction and therefore provide additional factors that regulate the strength of T cell activation.
20. 20 Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 1999; 283:680-682. See [19•].
21. 21 Lanzavecchia A, Lezzi G, Viola A. From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell 1999; 96:1-4.
22. 22 Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338:1813-1821. This is a concise review of the recent literature on the potential use of costimulation blockade in transplantation. See also [23•].
23. 23 Gudmundsdottir H, Turka LA. T cell costimulatory blockade: new therapies for transplant rejection. J Am Soc Nephrol 1999; 10:1356-1365. See [22•].
24. 24 Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. CTLA4lg-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103:1243-1252.
25. 25 Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, et al. CTLA4-lg and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94:8789-879.
26. 26 Chandraker A, Azuma H, Nadeau K, Carpenter CB, Tilney NL, Hancock WW, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998; 101:2309-2318.
27. 27 Schaub M, Stadlbauer TH, Chandraker A, Vella JP, Turka LA, Sayegh MH. Comparative strategies to induce long-term graft acceptance in fully allogeneic renal versus cardiac allograft models by CD28-B7 T cell costimulatory blockade: role of thymus and spleen. J Am Soc Nephrol 1998; 9:891-898.
28. 28 Markees TG, Phillips NE, Gordon EJ, Noelle RJ, Shultz LD, Mordes JP, et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998; 101:2446-2455. This study and [29•,30•] describe in detail the contribution of CTLA-4 to the establishment of graft tolerance in models of skin, islet and heart transplantation.
29. 29 Zheng XX, Markees TG, Hancock WW, Li Y, Greiner DL, Li XC, et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol 1999; 162:4983-4990. See [28•].
30. 30 Judge TA, Wu Z, Zheng XG, Sharpe AH, Sayegh MH, Turka LA. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol 1999; 162:1947-1951. See [28•].
31. 31 Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nature Med 1999; 5:686-693. This is a key paper that shows, in a model of renal transplantation in nonhuman primates, that treatment with anti-CD40L antibodies, without any other immunosuppression, might be feasible for the control of allograft rejection. It remains to be established what the long-term effects will be and how it will interfere with chronic rejection.
32. + T cell responses. Immunol Today 1996; 17:410-414.
33. 33 Stout RD, Suttles J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today 1996; 17:487-492.
34. 34 Mackey MF, Barth RJ Jr, Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol 1998; 63:418-428.
35. 35 Van Kooten C, Banchereau J. CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv immunol 1996; 61:1-77.
36. 36 Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, Van Kooten C, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12:881-922.
37. 37 Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391:591-594.
38. 38 Reul RM, Fang JC, Denton MD, Geehan C, Long C, Mitchell RN, et al. CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation 1997; 64:1765-1774.
39. 39 Biancone L, Segoloni G, Turello E, Donati D, Bussolati B, Piccoli G, et al. Expression of inducible lymphocyte costimulatory molecules in human renal allograft. Nephrol Dial Transplant 1998; 13:716-722.
40. 40 Gaweco AS, Mitchell BL, Lucas BA, McClatchey KD, Van Thiel DH. CD40 expression on graft infiltrates and parenchymal CD154 (CD40L) induction in human chronic renal allograft rejection. Kidney Int 1999; 55:1543-1552.
41. 41 Zheng XX, Schachter AD, Vasconceilos L, Strehlau J, Tian Y, Shapiro M, et al. Increased CD40 ligand gene expression during human renal and murine islet allograft rejection. Transplantation 1998; 65:1512-1515.
42. 42 Mach F, Schonbeck U, Fabunmi RP, Murphy C, Atkinson E, Bonnefoy JY, et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol 1999; 154:229-238.
43. 43 Schonbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med 1999; 189:843-853.
44. 44 Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394:200-203.
45. 45 Van Kooten C, Van der Linde X, Woltman AM, Van Es LA, Dana MR. Synergistic effect of IL-1 and CD40L on the activation of human renal tubular epithelial cells. Kidney Int 1999; 56:41-51. This paper demonstrates the important contribution that tubular epithelial cells might have in allograft rejection. CD40 activation of tubular epithelial cells, in synergy with interleukin-1, results in strong production of cytokines and chemokines.
46. 46 Van Kooten C, Gerritsma JSJ, Paape ME, Van Es LA, Banchereau J, Daha MR. Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int 1997; 51:711-721.
47. 47 Deckers JGM, De Haij S, Van der Woude FJ, Van der Kooij SW, Daha MR, Van Kooten C. IL-4 and IL-13 augment cytokine-and CD40-induced RANTES production by human renal tubular epithelial cells in vitro. J Am Soc Nephrol 1998; 9:1187-1193.
48. 48 Zhang Y, Cao HJ, Graf B, Meekins H, Smith TJ, Phipps RP. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol 1998; 160:1053-1057.
49. + T cells.
50. + T-helper and a T-killer cell. Nature 1998; 393:474-478. See [49•].
51. 51 Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393:480-483. See [49•].
52. 52 Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-252.
53. 53 Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283:1183-1186. This paper demonstrates that not only T cells, but also professional APCs can be divided in different subtypes. These cells induce different classes of immune responses, dependent on the different environmental conditions sensored by the APC.
54. 54 Thomson AW, Lu L. Are dendritic cells the key to liver transplant tolerance? Immunol Today 1999; 20:27-32.
55. 55 Sallusto F, Lanzavecchia A. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J Exp Med 1999; 189:611-614.
56. 56 Wong BR, Josien R, Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 1999; 65:715-724.